Global Psoriasis Drugs Market is estimated to be US$ 37.07 Billion in 2030 at a CAGR 8.9% during the forecast period - By PMI
10 févr. 2022 10h33 HE
|
PMI
Covina, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Global Psoriasis Drugs Market accounted for US$ 15.85 billion in 2020 and is estimated to be US$ 37.07 billion by 2030 and is anticipated to register a...
Plaque Psoriasis Epidemiology Forecast Report 2021: US will have the Highest Number of Cases in 2030, with 8,171,859
19 oct. 2021 06h33 HE
|
Research and Markets
Dublin, Oct. 19, 2021 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. Plaque psoriasis is the most common form...
HUMIRA (Adalimumab) Biosimilars Market Report 2021: Current Developer Landscape and Clinical Research Scenario Related to All the Follow-on Products of the Blockbuster Biologic Drug
30 juil. 2021 06h03 HE
|
Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "HUMIRA? (Adalimumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars,...
China's Infliximab Markets, 2016-2020 & 2021-2025 - Relevant Concepts, Sales, Major Manufacturers, Prices, Prospects
29 juil. 2021 08h33 HE
|
Research and Markets
Dublin, July 29, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Infliximab is a human-mouse...
Global Psoriasis Drugs Market Analysis and Demand Report 2021-2030: Rising Geriatric Population, Increasing Prevalence, Growing Awareness, Extensive Pipeline
03 juin 2021 06h53 HE
|
Research and Markets
Dublin, June 03, 2021 (GLOBE NEWSWIRE) -- The "Psoriasis Drugs Market Research Report: By Type, Mechanism of Action, Route of Administration - Global Industry Analysis and Demand Forecast to 2030"...
Global $2.27 Billion Adalimumab, Infliximab and Etanercept Biosimilars Market to 2030
03 févr. 2021 04h43 HE
|
Research and Markets
Dublin, Feb. 03, 2021 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to...